

Andrew J Saxon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9038824/publications.pdf>

Version: 2024-02-01

155
papers

5,645
citations

76196

40
h-index

98622

67
g-index

157
all docs

157
docs citations

157
times ranked

4932
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrating Routine Screening for Opioid Use Disorder into Primary Care Settings: Experiences from a National Cohort of Clinics. <i>Journal of General Internal Medicine</i> , 2023, 38, 332-340.	1.3	5
2	Pain, cannabis use, and physical and mental health indicators among veterans and nonveterans: results from the National Epidemiologic Survey on Alcohol and Related Conditions-III. <i>Pain</i> , 2022, 163, 267-273.	2.0	11
3	Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial. <i>Addiction</i> , 2022, 117, 151-161.	1.7	8
4	Prevalence and Correlates of Cannabis Use and Cannabis Use Disorder Among U.S. Veterans: Results From the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC-III). <i>American Journal of Psychiatry</i> , 2022, 179, 26-35.	4.0	22
5	Buprenorphine in safety-sensitive positions. <i>American Journal of Drug and Alcohol Abuse</i> , 2022, , 1-5.	1.1	1
6	Non-pharmacological Treatment for Chronic Pain in US Veterans Treated Within the Veterans Health Administration: Implications for Expansion in US Healthcare Systems. <i>Journal of General Internal Medicine</i> , 2022, 37, 3937-3946.	1.3	6
7	Introduction to the Special Series: National Drug Abuse Treatment Clinical Trials Network and the Opioid Use Disorder Care Continuum—20 years of research informing practice. <i>Addiction Science & Clinical Practice</i> , 2022, 17, 7.	1.2	0
8	Trends in Prescriptions for Non-opioid Pain Medications Among U.S. Adults With Moderate or Severe Pain, 2014-2018. <i>Journal of Pain</i> , 2022, 23, 1187-1195.	0.7	12
9	Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene. <i>European Journal of Clinical Pharmacology</i> , 2022, 78, 965-973.	0.8	1
10	Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 4106.	1.2	5
11	Clinical Documentation of Patient-Reported Medical Cannabis use in Primary Care: Toward Scalable Extraction using Natural Language Processing Methods. <i>Substance Abuse</i> , 2022, 43, 917-924.	1.1	6
12	Substance use disorders and COVID-19: An analysis of nation-wide Veterans Health Administration electronic health records. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109383.	1.6	14
13	Comparison of Medical Cannabis Use Reported on a Confidential Survey vs Documented in the Electronic Health Record Among Primary Care Patients. <i>JAMA Network Open</i> , 2022, 5, e2211677.	2.8	19
14	Primary Care Opioid Use Disorders treatment (PROUD) trial protocol: a pragmatic, cluster-randomized implementation trial in primary care for opioid use disorder treatment. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 9.	1.2	27
15	Prevalence and Medication Treatment of Opioid Use Disorder Among Primary Care Patients with Hepatitis C and HIV. <i>Journal of General Internal Medicine</i> , 2021, 36, 930-937.	1.3	7
16	Primary Care and Mental Health Prescribers, Key Clinical Leaders, and Clinical Pharmacist Specialists—Perspectives on Opioids and Benzodiazepines. <i>Pain Medicine</i> , 2021, 22, 1559-1569.	0.9	9
17	Combining behavioral harm-reduction treatment and extended-release naltrexone for people experiencing homelessness and alcohol use disorder in the USA: a randomised clinical trial. <i>Lancet Psychiatry</i> , 2021, 8, 287-300.	3.7	29
18	Is telemedicine the answer to rural expansion of medication treatment for opioid use disorder? Early experiences in the feasibility study phase of a National Drug Abuse Treatment Clinical Trials Network Trial. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 24.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Prevalence of Medical Cannabis Use and Associated Health Conditions Documented in Electronic Health Records Among Primary Care Patients in Washington State. <i>JAMA Network Open</i> , 2021, 4, e219375.	2.8	18
20	Imperative for Attention to Opioid Use Disorder and Other Substance Use Disorders in Older Adults. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 429-431.	0.6	1
21	High-Dose Buprenorphine Induction in the Emergency Department for Treatment of Opioid Use Disorder. <i>JAMA Network Open</i> , 2021, 4, e2117128.	2.8	63
22	Receipt of medications for opioid use disorder among youth engaged in primary care: data from 6 health systems. <i>Addiction Science & Clinical Practice</i> , 2021, 16, 46.	1.2	14
23	Video directly observed therapy for patients receiving office-based buprenorphine – A pilot randomized controlled trial. <i>Drug and Alcohol Dependence</i> , 2021, 227, 108917.	1.6	10
24	Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone. <i>Drug and Alcohol Dependence</i> , 2021, 228, 108996.	1.6	17
25	Elevated customary alcohol consumption attenuates opioid effects. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 211, 173295.	1.3	2
26	Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System. <i>JAMA Network Open</i> , 2021, 4, e2137238.	2.8	17
27	Prevalence and treatment of opioid use disorders among primary care patients in six health systems. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107732.	1.6	55
28	A Guide for Applying to Addiction Psychiatry Fellowship. <i>Academic Psychiatry</i> , 2020, 44, 135-140.	0.4	6
29	Acceptability and Feasibility of a Mobile Health Application for Video Directly Observed Therapy of Buprenorphine for Opioid Use Disorders in an Office-based Setting. <i>Journal of Addiction Medicine</i> , 2020, 14, 319-325.	1.4	16
30	Relationship of Phosphatidylethanol Biomarker to Self-Reported Alcohol Drinking Patterns in Older and Middle-Age Adults. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2449-2456.	1.4	10
31	Secondary Analysis of Pain Outcomes in a Large Pragmatic Randomized Trial of Buprenorphine/Naloxone Versus Methadone for Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2020, 14, e188-e194.	1.4	8
32	Long-term Buprenorphine Treatment for Loperamide Use Disorder: A Case Series. <i>Journal of Addiction Medicine</i> , 2020, 14, e378-e381.	1.4	2
33	Developing a clinical decision support for opioid use disorders: a NIDA center for the clinical trials network working group report. <i>Addiction Science & Clinical Practice</i> , 2020, 15, 4.	1.2	11
34	Documented opioid use disorder and its treatment in primary care patients across six U.S. health systems. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 41-48.	1.5	34
35	Potential for Precision Medicine in Methadone Treatment of Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2020, 14, 362-363.	1.4	3
36	Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder. <i>Journal of Substance Abuse Treatment</i> , 2019, 106, 19-28.	1.5	21

#	ARTICLE	IF	CITATIONS
37	Prazosin for Alcohol Use Disorder: Response to Kleinman and Ostacher. <i>American Journal of Psychiatry</i> , 2019, 176, 165-166.	4.0	1
38	Provider and patient perspectives on barriers to buprenorphine adherence and the acceptability of video directly observed therapy to enhance adherence. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 11.	1.2	37
39	Harm Reduction Treatment for Smoking (HaRT-S): Findings from a Single-Arm Pilot Study with Smokers Experiencing Chronic Homelessness. <i>Substance Abuse</i> , 2019, 40, 229-239.	1.1	9
40	Escalating Opioid Dose Is Associated With Mortality: A Comparison of Patients With and Without Opioid Use Disorder. <i>Journal of Addiction Medicine</i> , 2019, 13, 41-46.	1.4	21
41	Medications to treat cocaine use disorders. <i>Current Opinion in Psychiatry</i> , 2019, 32, 275-281.	3.1	19
42	Use of Prolonged Exposure and Sertraline in the Treatment of Posttraumatic Stress Disorder for Veterans. <i>JAMA Psychiatry</i> , 2019, 76, 109.	6.0	4
43	Extended-release naltrexone (XR-NTX) for opioid use disorder in clinical practice: Vivitrol's Cost and Treatment Outcomes Registry. <i>Addiction</i> , 2018, 113, 1477-1487.	1.7	21
44	Electronic Medical Record Alert Associated With Reduced Opioid and Benzodiazepine Coprescribing in High-risk Veteran Patients. <i>Medical Care</i> , 2018, 56, 171-178.	1.1	30
45	The Role of Cannabis Legalization in the Opioid Crisis. <i>JAMA Internal Medicine</i> , 2018, 178, 679.	2.6	16
46	Alcohol-Related Nurse Care Management in Primary Care. <i>JAMA Internal Medicine</i> , 2018, 178, 613.	2.6	33
47	Double-Blind Randomized Clinical Trial of Prazosin for Alcohol Use Disorder. <i>American Journal of Psychiatry</i> , 2018, 175, 1216-1224.	4.0	59
48	The Addiction Solution: Treating Our Dependence on Opioids and Other Drugs by Lloyd I. Sederer, M.D. New York, Simon & Schuster, 2018, 224 pp., \$26.00 (hardcover).. <i>American Journal of Psychiatry</i> , 2018, 175, 688-689.	4.0	0
49	Correlates of Long-Term Opioid Abstinence After Randomization to Methadone Versus Buprenorphine/Naloxone in a Multi-Site Trial. <i>Journal of Neuroimmune Pharmacology</i> , 2018, 13, 488-497.	2.1	50
50	The Unmet Challenges of Co-Occurring Alcohol and Opioid Use. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 1406-1407.	1.4	5
51	Survey of Primary Care and Mental Health Prescribers' Perspectives on Reducing Opioid and Benzodiazepine Co-Prescribing Among Veterans. <i>Pain Medicine</i> , 2017, 18, pnw140.	0.9	23
52	Methadone "callbacks" within a veterans affairs opioid treatment program: Detecting methadone misuse. <i>American Journal on Addictions</i> , 2017, 26, 50-52.	1.3	1
53	A phase III, randomized, multi-center, double blind, placebo controlled study of safety and efficacy of lofexidine for relief of symptoms in individuals undergoing inpatient opioid withdrawal. <i>Drug and Alcohol Dependence</i> , 2017, 176, 79-88.	1.6	52
54	High Mortality Among Patients With Opioid Use Disorder in a Large Healthcare System. <i>Journal of Addiction Medicine</i> , 2017, 11, 315-319.	1.4	125

#	ARTICLE	IF	CITATIONS
55	Causes of death and expected years of life lost among treated opioid-dependent individuals in the United States and Taiwan. <i>International Journal of Drug Policy</i> , 2017, 43, 1-6.	1.6	24
56	Chronic pain among patients with opioid use disorder: Results from electronic health records data. <i>Journal of Substance Abuse Treatment</i> , 2017, 77, 26-30.	1.5	137
57	Distinctive Trajectories of Opioid Use Over an Extended Follow-up of Patients in a Multisite Trial on Buprenorphine+Naloxone and Methadone. <i>Journal of Addiction Medicine</i> , 2017, 11, 63-69.	1.4	54
58	Prevalence of Alcohol Misuse and Follow-Up Care in a National Sample of OEF/OIF VA Patients With and Without TBI. <i>Psychiatric Services</i> , 2017, 68, 48-55.	1.1	35
59	Providing intensive addiction/housing case management to homeless veterans enrolled in addictions treatment: A randomized controlled trial.. <i>Psychology of Addictive Behaviors</i> , 2017, 31, 231-241.	1.4	12
60	Characteristics and service utilization of homeless veterans entering VA substance use treatment.. <i>Psychological Services</i> , 2017, 14, 208-213.	0.9	12
61	Some Additional Considerations Regarding the American Society of Addiction Medicine National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use. <i>Journal of Addiction Medicine</i> , 2016, 10, 140-142.	1.4	11
62	Buprenorphine+Naloxone plus naltrexone for the treatment of cocaine dependence: the Cocaine Use Reduction with Buprenorphine (CURB) study. <i>Addiction</i> , 2016, 111, 1416-1427.	1.7	53
63	A narrative review: The effects of opioids on sleep disordered breathing in chronic pain patients and methadone maintained patients. <i>American Journal on Addictions</i> , 2016, 25, 452-465.	1.3	40
64	Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multisite trial. <i>Addiction</i> , 2016, 111, 695-705.	1.7	165
65	Cost-Effectiveness of Integrating Tobacco Cessation Into Post-Traumatic Stress Disorder Treatment. <i>Nicotine and Tobacco Research</i> , 2016, 18, 267-274.	1.4	9
66	Treatment outcomes in opioid dependent patients with different buprenorphine/naloxone induction dosing patterns and trajectories. <i>American Journal on Addictions</i> , 2015, 24, 667-675.	1.3	25
67	Extended-Release Naltrexone and Harm Reduction Counseling for Chronically Homeless People With Alcohol Dependence. <i>Substance Abuse</i> , 2015, 36, 21-33.	1.1	25
68	Prevalence and Trends of Concurrent Opioid Analgesic and Benzodiazepine Use Among Veterans Affairs Patients with Post-traumatic Stress Disorder, 2003-2011. <i>Pain Medicine</i> , 2015, 16, 1943-1954.	0.9	38
69	Quetiapine for the treatment of cocaine use disorder. <i>Drug and Alcohol Dependence</i> , 2015, 149, 18-24.	1.6	13
70	Tobacco use trajectories among a large cohort of treated smokers with posttraumatic stress disorder. <i>Addictive Behaviors</i> , 2015, 41, 238-246.	1.7	8
71	Comparative safety of methadone and buprenorphine. <i>Lancet Psychiatry</i> , 2015, 2, 855-856.	3.7	3
72	A Pilot Trial of Prazosin, an Alpha-1 Adrenergic Antagonist, for Comorbid Alcohol Dependence and Posttraumatic Stress Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 808-817.	1.4	73

#	ARTICLE	IF	CITATIONS
73	Commentary on Burns <i>et al</i> . (2015): Retention in buprenorphine treatment. <i>Addiction</i> , 2015, 110, 656-657.	1.7	6
74	HIV Risk Reduction With Buprenorphine+Naloxone or Methadone. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2014, 66, 288-293.	0.9	77
75	Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. <i>Addiction</i> , 2014, 109, 79-87.	1.7	345
76	Clinical monitoring and high-risk conditions among patients with SUD newly prescribed opioids and benzodiazepines. <i>Drug and Alcohol Dependence</i> , 2014, 142, 24-32.	1.6	8
77	Marijuana not ready for prime time as an analgesic. <i>General Hospital Psychiatry</i> , 2014, 36, 4-6.	1.2	5
78	Harm reduction with pharmacotherapy for homeless people with alcohol dependence: Protocol for a randomized controlled trial. <i>Contemporary Clinical Trials</i> , 2014, 38, 221-234.	0.8	8
79	Longitudinal analysis of the relationship between PTSD symptom clusters, cigarette use, and physical health-related quality of life. <i>Quality of Life Research</i> , 2013, 22, 1381-1389.	1.5	13
80	Medication-assisted therapy for opioid addiction. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S13-S15.	0.9	7
81	Cocaine Use Reduction with Buprenorphine (CURB): Rationale, design, and methodology. <i>Contemporary Clinical Trials</i> , 2013, 34, 196-204.	0.8	22
82	Medication-assisted treatment for opioid addiction: Methadone and buprenorphine. <i>Journal of Food and Drug Analysis</i> , 2013, 21, S69-S72.	0.9	36
83	Buprenorphine/Naloxone and methadone effects on laboratory indices of liver health: A randomized trial. <i>Drug and Alcohol Dependence</i> , 2013, 128, 71-76.	1.6	94
84	An Intronic Variant in OPRD1 Predicts Treatment Outcome for Opioid Dependence in African-Americans. <i>Neuropsychopharmacology</i> , 2013, 38, 2003-2010.	2.8	74
85	Comparative Safety of Benzodiazepines and Opioids Among Veterans Affairs Patients With Posttraumatic Stress Disorder. <i>Journal of Addiction Medicine</i> , 2013, 7, 354-362.	1.4	16
86	Survey of providers' attitudes toward integrating smoking cessation treatment into posttraumatic stress disorder care. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 249-255.	1.4	16
87	Smoking Outcome Expectancies in Military Veteran Smokers With Posttraumatic Stress Disorder. <i>Nicotine and Tobacco Research</i> , 2012, 14, 919-926.	1.4	22
88	PTSD and depression as predictors of physical health-related quality of life in tobacco-dependent veterans. <i>Journal of Psychosomatic Research</i> , 2012, 73, 185-190.	1.2	26
89	Prevalence and trends of benzodiazepine use among Veterans Affairs patients with posttraumatic stress disorder, 2003-2010. <i>Drug and Alcohol Dependence</i> , 2012, 124, 154-161.	1.6	41
90	Smoking intensity and severity of specific symptom clusters in posttraumatic stress disorder. <i>Journal of Traumatic Stress</i> , 2012, 25, 10-16.	1.0	27

#	ARTICLE	IF	CITATIONS
91	Buprenorphine therapy for opioid addiction in rural Washington: The experience of the early adopters. <i>Journal of Opioid Management</i> , 2012, 8, 29-38.	0.2	49
92	The Influence of Posttraumatic Stress Disorder Numbing and Hyperarousal Symptom Clusters in the Prediction of Physical Health Status in Veterans With Chronic Tobacco Dependence and Posttraumatic Stress Disorder. <i>Journal of Nervous and Mental Disease</i> , 2011, 199, 940-945.	0.5	24
93	Associations of Housing Status With Substance Abuse Treatment and Service Use Outcomes Among Veterans. <i>Psychiatric Services</i> , 2010, 61, 698-706.	1.1	33
94	Integrating Tobacco Cessation Into Mental Health Care for Posttraumatic Stress Disorder–A Randomized Controlled Trial–. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2485.	3.8	188
95	The Physician Clinical Support System-Buprenorphine (PCSS-B): a Novel Project to Expand/Improve Buprenorphine Treatment. <i>Journal of General Internal Medicine</i> , 2010, 25, 936-941.	1.3	59
96	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S53-S60.	1.5	45
97	LONG-SUFFERING OR PROLONGED SUFFERING? TIME MATTERS. <i>Addiction</i> , 2009, 104, 1429-1430.	1.7	2
98	A Pilot Trial of the Alpha-1 Adrenergic Antagonist, Prazosin, for Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2009, 33, 255-263.	1.4	147
99	Buprenorphine tapering schedule and illicit opioid use. <i>Addiction</i> , 2009, 104, 256-265.	1.7	103
100	Factors affecting willingness to provide buprenorphine treatment. <i>Journal of Substance Abuse Treatment</i> , 2009, 36, 244-251.	1.5	150
101	Open Trial of Injectable Risperidone for Methamphetamine Dependence. <i>Journal of Addiction Medicine</i> , 2009, 3, 55-65.	1.4	12
102	The association of persistent pain with outpatient addiction treatment outcomes and service utilization. <i>Addiction</i> , 2008, 103, 1996-2005.	1.7	98
103	Quetiapine for the Treatment of Cocaine Dependence. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 221-224.	0.7	23
104	Post-traumatic stress disorder and smoking: A systematic review. <i>Nicotine and Tobacco Research</i> , 2007, 9, 1071-1084.	1.4	225
105	Integrating smoking cessation into mental health care for post-traumatic stress disorder. <i>Clinical Trials</i> , 2007, 4, 178-189.	0.7	28
106	Further Validation of the Alcohol Dependence Scale as an Index of Severity*. <i>Journal of Studies on Alcohol and Drugs</i> , 2007, 68, 149-156.	0.6	12
107	Implementation of buprenorphine in the Veterans Health Administration: Results of the first 3 years. <i>Drug and Alcohol Dependence</i> , 2007, 90, 292-296.	1.6	40
108	An Open-Label Pilot Study of Risperidone in the Treatment of Methamphetamine Dependence. <i>Journal of Psychoactive Drugs</i> , 2007, 39, 167-172.	1.0	30

#	ARTICLE	IF	CITATIONS
109	Single Dose of 24 Milligrams of Buprenorphine for Heroin Detoxification: An Open-label Study of Five Inpatients. <i>Journal of Psychoactive Drugs</i> , 2006, 38, 505-512.	1.0	17
110	Slow tapering from methadone maintenance in a program encouraging indefinite maintenance. <i>Journal of Substance Abuse Treatment</i> , 2006, 30, 159-163.	1.5	44
111	Pharmacokinetic Profile of an Oral Loading Dose of Divalproex Sodium During Acute Alcohol Withdrawal. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 105-107.	0.7	2
112	Integrating Tobacco Cessation Treatment into Mental Health Care for Patients with Posttraumatic Stress Disorder. <i>American Journal on Addictions</i> , 2006, 15, 336-344.	1.3	39
113	Methadone medical maintenance in primary care. <i>Journal of General Internal Medicine</i> , 2005, 20, 344-349.	1.3	37
114	Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. , 2005, 108, 119-128.		49
115	Genetic Determinants of Addiction to Opioids and Cocaine. <i>Harvard Review of Psychiatry</i> , 2005, 13, 218-232.	0.9	44
116	A Comparison of Methamphetamine-Dependent Inpatients With and Without Childhood Attention Deficit Hyperactivity Disorder Symptomatology. <i>Journal of Addictive Diseases</i> , 2005, 24, 133-152.	0.8	56
117	Improving the Rates of Quitting Smoking for Veterans With Posttraumatic Stress Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 1311-1319.	4.0	102
118	Can an Immunoassay Become a Standard Technique in Detecting Oxycodone and Its Metabolites?. <i>Journal of Analytical Toxicology</i> , 2005, 29, 825-829.	1.7	8
119	A double-blind, double-dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. <i>Drug and Alcohol Dependence</i> , 2005, 77, 71-79.	1.6	48
120	Implications of Chronic Methamphetamine Use: A Literature Review. <i>Harvard Review of Psychiatry</i> , 2005, 13, 141-154.	0.9	332
121	The Addiction Severity Index medical and psychiatric composite scores measure similar domains as the SF-36 in substance-dependent veterans: concurrent and discriminant validity. <i>Drug and Alcohol Dependence</i> , 2004, 76, 165-171.	1.6	60
122	Use of Veterans Affairs Health Care Services by Veterans Receiving Addiction Treatment in Washington State.. <i>Psychological Services</i> , 2004, 1, 120-125.	0.9	3
123	Brief motivational feedback improves post-incarceration treatment contact among veterans with substance use disorders. <i>Drug and Alcohol Dependence</i> , 2003, 69, 197-203.	1.6	60
124	Transporting efficacious treatments from academia to community: barriers and opportunities. <i>Drug and Alcohol Dependence</i> , 2003, 70, 127-129.	1.6	4
125	Smoking cessation treatment among dually diagnosed individuals: Preliminary evaluation of different pharmacotherapies. <i>Nicotine and Tobacco Research</i> , 2003, 5, 589-596.	1.4	24
126	The Alcohol Use Disorders Identification Test (AUDIT) Predicts Alcohol Withdrawal Symptoms During Inpatient Detoxification. <i>Journal of Addictive Diseases</i> , 2002, 21, 81-91.	0.8	15

#	ARTICLE	IF	CITATIONS
127	Women in addictions treatment: comparing VA and community samples. <i>Journal of Substance Abuse Treatment</i> , 2002, 23, 41-48.	1.5	22
128	Trauma, Symptoms of Posttraumatic Stress Disorder, and Associated Problems Among Incarcerated Veterans. <i>Psychiatric Services</i> , 2001, 52, 959-964.	1.1	107
129	Divalproex Sodium in Alcohol Withdrawal: A Randomized Double-Blind Placebo-Controlled Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2001, 25, 1324-1329.	1.4	105
130	Changes in Millon Clinical Multiaxial Inventory Scores Among Opiate Addicts as a Function of Retention in Methadone Maintenance Treatment and Recent Drug Use. <i>American Journal of Drug and Alcohol Abuse</i> , 2000, 26, 297-309.	1.1	27
131	Detecting Bipolar Disorder Among Treatment-Seeking Substance Abusers. <i>American Journal of Drug and Alcohol Abuse</i> , 2000, 26, 13-23.	1.1	10
132	A Pilot Study Comparing Severely and Persistently Mentally Ill Opiate-Addicted Patients in Dual-Diagnosis Treatment With Patients in Methadone Maintenance. <i>American Journal on Addictions</i> , 1998, 7, 288-298.	1.3	1
133	The Use of Urine Toxicology to Enhance Patient Control of Take-Home Doses in Methadone Maintenance: Effects on Reducing Illicit Drug Use. <i>Addiction Research</i> , 1998, 6, 203-214.	0.6	2
134	Disulfiram Use in Patients With Abnormal Liver Function Test Results. <i>Journal of Clinical Psychiatry</i> , 1998, 59, 313-316.	1.1	25
135	An open trial of transdermal nicotine replacement therapy for smoking cessation among alcohol- and drug-dependent inpatients. <i>Journal of Substance Abuse Treatment</i> , 1997, 14, 333-337.	1.5	48
136	Outcome of a second episode of methadone maintenance. <i>Drug and Alcohol Dependence</i> , 1996, 43, 163-168.	1.6	2
137	Clinical Issues Related to the Costs of Alcoholism. <i>Pharmacoeconomics</i> , 1996, 9, 134-145.	1.7	7
138	Personality disorder subtypes among opiate addicts in methadone maintenance.. <i>Psychology of Addictive Behaviors</i> , 1996, 10, 3-8.	1.4	16
139	Pre-treatment characteristics, program philosophy and level of ancillary services as predictors of methadone maintenance treatment outcome. <i>Addiction</i> , 1996, 91, 1197-1210.	1.7	116
140	Retention in Methadone Maintenance Is Associated with Reductions in Different HIV Risk Behaviors for Women and Men. <i>American Journal of Drug and Alcohol Abuse</i> , 1996, 22, 509-521.	1.1	44
141	Effects of Psychiatric Care for Dual Diagnosis Patients Treated in a Drug Dependence Clinic. <i>American Journal of Drug and Alcohol Abuse</i> , 1995, 21, 303-313.	1.1	26
142	Acupuncture as an Adjunct to Methadone Treatment Services. <i>American Journal on Addictions</i> , 1995, 4, 198-214.	1.3	29
143	Contingency Management of Urinalysis Results and Intensity of Counseling Services Have an Interactive Impact on Methadone Maintenance Treatment Outcome. <i>Journal of Addictive Diseases</i> , 1995, 13, 47-63.	0.8	35
144	Analysis of Urinary Benzodiazepines Using Solid-Phase Extraction and Gas Chromatography-Mass Spectrometry. <i>Journal of Analytical Toxicology</i> , 1994, 18, 185-188.	1.7	56

#	ARTICLE	IF	CITATIONS
145	Longitudinal changes in injection behaviors in a cohort of injection drug users. <i>Addiction</i> , 1994, 89, 191-202.	1.7	34
146	Using the General Behavior Inventory to Screen for Mood Disorders Among Patients With Psychoactive Substance Dependence. <i>American Journal on Addictions</i> , 1994, 3, 296-305.	1.3	7
147	Using the General Behavior Inventory to Screen for Mood Disorders Among Patients with Psychoactive Substance Dependence. <i>American Journal on Addictions</i> , 1994, 3, 296-305.	1.3	5
148	Outcome of contingency contracting for illicit drug use in a methadone maintenance program. <i>Drug and Alcohol Dependence</i> , 1993, 31, 205-214.	1.6	26
149	Urine Screening for Marijuana Among Methadone-Maintained Patients. <i>American Journal on Addictions</i> , 1993, 2, 207-211.	1.3	1
150	Comparison of HIV-Associated Risk Behaviors of Primary Intravenous Stimulant Users and Opioid-Addicted Subjects on Methadone Maintenance. <i>American Journal on Addictions</i> , 1992, 1, 304-314.	1.3	4
151	Comparison of HIV-Associated Risk Behaviors of Primary Intravenous Stimulant Users and Opioid-Addicted Subjects on Methadone Maintenance. <i>American Journal on Addictions</i> , 1992, 1, 304-314.	1.3	0
152	Validity of the MCMI Drug Abuse Scale Varies as a Function of Drug Choice, Race, and Axis II Subtypes. <i>American Journal of Drug and Alcohol Abuse</i> , 1991, 17, 153-159.	1.1	7
153	Personality Disorder Subtypes Among Cocaine and Opioid Addicts Using the Millon Clinical Multiaxial Inventory. <i>Substance Use and Misuse</i> , 1990, 25, 1037-1049.	0.6	31
154	Validity of the MCMI drug abuse scale with drug abusing and psychiatric samples. <i>Journal of Clinical Psychology</i> , 1990, 46, 244-246.	1.0	13
155	A system for uniform application of contingencies for illicit drug use. <i>Journal of Substance Abuse Treatment</i> , 1987, 4, 41-47.	1.5	21